Magazine
Latest Issue

Michael Rawlins

The chairman of Nice—the body that decides which drugs the NHS can afford—on the Herceptin row, how Nice calculates the value of a human life and the pharmaceutical industry's expensive drugs crisis

By Alun Anderson   February 2007

Since it was set up in 1999, the National Institute for Health and Clinical Excellence, or Nice, has rarely been out of the news. Turn to one newspaper and it is “the government’s drug rationing watchdog,” denying suffering patients access to drugs in order to save the NHS a few miserable pounds. Turn elsewhere and Nice is a brave attempt to bring rationality and best practice into the provision of healthcare.

When it opened for business (then just called the National Institute for Clinical Excellence) provision of healthcare in Britain was subject to a postcode lottery, with different drugs and…

Register today to continue reading

You’ve hit your limit of three articles in the last 30 days. To get seven more, simply enter your email address below.

You’ll also receive our free e-book Prospect’s Top Thinkers 2020 and our newsletter with the best new writing on politics, economics, literature and the arts.

Prospect may process your personal information for our legitimate business purposes, to provide you with newsletters, subscription offers and other relevant information.

Click here to learn more about these purposes and how we use your data. You will be able to opt-out of further contact on the next page and in all our communications.

We want to hear what you think about this article. Submit a letter to letters@prospect-magazine.co.uk

More From Prospect